KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Short term Debt: 2017-2020

Historic Short term Debt for Xenon Pharmaceuticals (XENE) over the last 1 years, with Mar 2020 value amounting to $15.7 million.

  • Xenon Pharmaceuticals' Short term Debt was N/A to $15.7 million in Q1 2020 from the same period last year, while for Mar 2020 it was $15.7 million, marking a year-over-year change of. This contributed to the annual value of $4.7 million for FY2019, which is N/A change from last year.
  • Per Xenon Pharmaceuticals' latest filing, its Short term Debt stood at $15.7 million for Q1 2020, which was up 237.12% from $4.7 million recorded in Q4 2019.
  • Over the past 5 years, Xenon Pharmaceuticals' Short term Debt peaked at $15.7 million during Q1 2020, and registered a low of $700,000 during Q4 2017.
  • For the 3-year period, Xenon Pharmaceuticals' Short term Debt averaged around $5.5 million, with its median value being $3.6 million (2019).